当前位置: 首页 >> 检索结果
1. Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial.
作者: Wijnand A C Palmbergen.;Roy Beekman.;A Marijne Heeren.;Bart F L van Nuenen.;Tim W H Alleman.;Esther Verstraete.;Korné Jellema.;Wim I M Verhagen.;Leo H Visser.;Godard C W de Ruiter.;Diederik van de Beek.;Corianne A J M de Borgie.;Johannes A Bogaards.;Rob M A de Bie.;Camiel Verhamme.; .
来源: Lancet. 2025年405卷10495期2153-2163页
Surgery and corticosteroid injections are established treatments for carpal tunnel syndrome, but the optimal treatment strategy remains unclear. This study aimed to compare starting treatment with surgery versus starting with a corticosteroid injection.
2. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
作者: Sheela Rao.;Emmanuelle Samalin-Scalzi.;Ludovic Evesque.;Meher Ben Abdelghani.;Federica Morano.;Amitesh Roy.;Laetitia Dahan.;Stefano Tamberi.;Amandeep Singh Dhadda.;Mark P Saunders.;Nathalie Casanova.;Rosine Guimbaud.;Astrid Lievre.;Joan Maurel.;Marwan Fakih.;Chuan Tian.;Jill Harrison.;Mark M Jones.;Mark Cornfeld.;Jean-Philippe Spano.;Pauline Rochefort.; .
来源: Lancet. 2025年405卷10495期2144-2152页
Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease.
3. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
作者: Luis Paz-Ares.;Hossein Borghaei.;Stephen V Liu.;Solange Peters.;Roy S Herbst.;Katarzyna Stencel.;Margarita Majem.;Mehmet Ali Nahit Şendur.;Grzegorz Czyżewicz.;Reyes Bernabé Caro.;Ki Hyeong Lee.;Melissa L Johnson.;Nuri Karadurmuş.;Christian Grohé.;Sofia Baka.;Tibor Csőszi.;Jin Seok Ahn.;Raffaele Califano.;Tsung-Ying Yang.;Yasemin Kemal.;Marcus Ballinger.;Vaikunth Cuchelkar.;Vilma Graupner.;Ya-Chen Lin.;Debasis Chakrabarti.;Kamalnayan Bhatt.;George Cai.;Robert Iannone.;Martin Reck.; .
来源: Lancet. 2025年405卷10495期2129-2143页
Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival remains poor. In this study, we aimed to compare lurbinectedin plus atezolizumab and atezolizumab alone as maintenance therapies in patients with ES-SCLC without progression after induction therapy with atezolizumab, carboplatin, and etoposide.
4. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
作者: Changsong Qi.;Chang Liu.;Zhi Peng.;Yanqiao Zhang.;Jia Wei.;Wensheng Qiu.;Xiaotian Zhang.;Hongming Pan.;Zuoxing Niu.;Meng Qiu.;Yanru Qin.;Weijia Fang.;Feng Ye.;Ning Li.;Tianshu Liu.;Anwen Liu.;Xizhi Zhang.;Changlu Hu.;Jun Zhang.;Jiuwei Cui.;Xiaoyan Lin.;Shubin Wang.;Jian Zhang.;Tongyu Lin.;Xiujuan Qu.;Xianglin Yuan.;Jifang Gong.;Jian Li.;Wanwan Gao.;Lun Gai.;Yumeng Wang.;Daijing Yuan.;Zonghai Li.;Lin Shen.
来源: Lancet. 2025年405卷10494期2049-2060页
Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in previously treated patients with advanced gastric or gastro-oesophageal junction cancer in phase 1 clinical trials. In this Article, we report the primary results from the phase 2 pivotal trial (CT041-ST-01) investigating the efficacy and safety of satri-cel for gastric or gastro-oesophageal junction cancer.
5. Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.
作者: Craig S Anderson.;Debbie Summers.;Menglu Ouyang.;Yi Sui.;Brenda Johnson.;Laurent Billot.;Alejandra Malavera.;Roland Faigle.;Paula Muñoz-Venturelli.;Diana Day.;Xiaoqiu Liu.;Qiang Li.;Lili Song.;Thompson G Robinson.;Francisca González.;Francisca Urrutia-Goldsack.;Michael Iacobelli.;Michelle Montalbano.;April Pruski.;Candice Delcourt.;Alice C Durham.;Ahtasam Ebraimo.;Ha Hong Van Ta.;Pratiti Ghosh.;Ann Leonhardt-Caprio.;Huy Thang Nguyen.;Mai Duy Ton.;Stephen Jan.;Hueiming Liu.;Richard I Lindley.;Antonio Arauz.;Andrés Mercado.;Wan Asyraf Wan Zaidi.;Pooja Khatri.;Xia Wang.;Victor C Urrutia.; .
来源: Lancet. 2025年405卷10493期1909-1922页
The universally accepted best practice protocol for monitoring patients who receive intravenous thrombolysis for acute ischaemic stroke was established in the 1990s. However, the protocol is burdensome for nurses, disrupts the sleep of patients, and is potentially less relevant in patients at low risk of symptomatic intracerebral haemorrhage. We aimed to assess whether implementing a low-intensity monitoring protocol would be as safe and effective as standard high-intensity monitoring for patients with acute ischaemic stroke at low risk.
6. Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
作者: Fiona J Gilbert.;Nicholas R Payne.;Iris Allajbeu.;Lim Yit.;Sarah Vinnicombe.;Iain Lyburn.;Nisha Sharma.;Will Teh.;Jonathan James.;Archana Seth.;Tamara Suaris.;Reena Aggarwal.;Miaad Al-Attar.;Sarah Savaridas.;Antonis Antoniou.;Paul Pharoah.;Stephen Duffy.
来源: Lancet. 2025年405卷10493期1935-1944页
It is not known which supplemental imaging technique is most beneficial for women with dense breasts attending breast screening. This study compares abbreviated MRI, automated whole breast ultrasound (ABUS), and contrast-enhanced mammography versus standard of care in women with dense breasts and a negative mammogram. We report on interim results from the first round of supplemental imaging.
7. ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.
作者: Raj R Makkar.;Ravi K Ramana.;Eric Gnall.;Basel Ramlawi.;Wen Cheng.;Pantelis Diamantouros.;Srinivasa Potluri.;Neal Kleinman.;Aakriti Gupta.;Tarun Chakravarty.;Sanjay Samy.;Andrew Rassi.;Vivek Rajagopal.;Steven Yakubov.;Paul Sorajja.;Dhairya Patel.;Santiago Garcia.;Pradeep Yadav.;Vinod Thourani.;John Wang.;Michael Rinaldi.;Samir Kapadia.;Ron Waksman.;John Webb.;Claire Ben Ren.;John Gregson.;Rodrigo Modolo.;Janarthanan Sathananthan.;Michael J Reardon.; .
来源: Lancet. 2025年405卷10494期2061-2074页
ACURATE neo2 is an open-cell, supra-annular, self-expanding transcatheter heart valve that is commercially available in over 50 countries but has not previously been evaluated in a randomised trial. ACURATE-IDE aimed to prospectively evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with the ACURATE neo2 valve compared with commercially available valves for the treatment of severe symptomatic aortic stenosis.
8. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.
作者: Beryl B Cummings.;Mark P Joing.;Page R Bouchard.;Mark N Milton.;Peter F Moesta.;Vyas Ramanan.;Andrew Lane.;Joe Hirman.;John W Trauger.;Eleftheria Maratos-Flier.;Andrei Voznesensky.;Igor Splawski.;Amitabh V Nimonkar.;Meghan M Flaherty.;B Alexander Yi.;Daniel Meyers.;Francois Huet.;Sukhdeep K Sahambi.;Denise P Yates.;Douglas Hom.;Markus Hinder.;Craig T Basson.;Chris O'Donnell.;Evan S Siegelman.;Chris E Garrett.;Joshua Lehrer-Graiwer.;Rebecca A Juliano.;Ethan J Weiss.
来源: Lancet. 2025年405卷10493期1923-1934页
Genetic studies have established angiopoietin-related protein 4 (ANGPTL4) as a key regulator of triglyceride metabolism and a promising target to reduce atherosclerotic cardiovascular disease (ASCVD) risk beyond traditional risk factors. Human ANGPTL4 loss-of-function shows no adverse consequences and is associated with reduced triglycerides and remnant cholesterol, and a reduced risk of type 2 diabetes and ASCVD. Nonetheless, development of ANGPTL4 inhibitors has been delayed due to adverse findings in ANGPTL4-knockout mice fed a high saturated fat diet, including lipid accumulation in mesenteric lymph nodes, systemic inflammation, adverse clinical signs, and reduced survival. We previously reported the development and preclinical characterisation of MAR001, an ANGPTL4 inhibitory antibody. Here, we report a comprehensive safety assessment of ANGPTL4 inhibition, including novel analysis of genetic ANGPTL4 loss on mesenteric lymph node architecture in humans and two early-phase clinical trials.
9. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.
作者: Gilbert Bensimon.;P Nigel Leigh.;Timothy Tree.;Andrea Malaspina.;Christine Am Payan.;Hang-Phuong Pham.;Pieter Klaassen.;Pamela J Shaw.;Ahmad Al Khleifat.;Maria D M Amador.;Shahram Attarian.;Simon M Bell.;Stéphane Beltran.;Emilien Bernard.;William Camu.;Philippe Corcia.;Jean-Christophe Corvol.;Philippe Couratier.;Véronique Danel.;Rabab Debs.;Claude Desnuelle.;Aikaterini Dimitriou.;John Ealing.;Florence Esselin.;Marie-Céline Fleury.;George H Gorrie.;Aude-Marie Grapperon.;Adèle Hesters.;Raul Juntas-Morales.;Ivan Kolev.;Géraldine Lautrette.;Nadine Le Forestier.;Christopher J McDermott.;Nicolas Pageot.;François Salachas.;Nikhil Sharma.;Marie-Hélène Soriani.;Jemeen Sreedharan.;Juliette Svahn.;Nick Verber.;Annie Verschueren.;Ozlem Yildiz.;Carey M Suehs.;Safaa Saker-Delye.;Claudie Muller.;Christophe Masseguin.;Hana Hajduchova.;Janine Kirby.;Cecilia Garlanda.;Massimo Locati.;Henrik Zetterberg.;Bernard Asselain.;Ammar Al-Chalabi.; .
来源: Lancet. 2025年405卷10492期1837-1850页
Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.
10. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
作者: Thomas Yau.;Peter R Galle.;Thomas Decaens.;Bruno Sangro.;Shukui Qin.;Leonardo G da Fonseca.;Hatim Karachiwala.;Jean-Frederic Blanc.;Joong-Won Park.;Edward Gane.;Matthias Pinter.;Ana Matilla Peña.;Masafumi Ikeda.;David Tai.;Armando Santoro.;Gonzalo Pizarro.;Chang-Fang Chiu.;Michael Schenker.;Aiwu He.;Hong Jae Chon.;Joanna Wojcik-Tomaszewska.;Gontran Verset.;Qi Qi Wang.;Caitlyn Stromko.;Jaclyn Neely.;Prianka Singh.;Maria Jesus Jimenez Exposito.;Masatoshi Kudo.; .
来源: Lancet. 2025年405卷10492期1851-1864页
Patients with unresectable hepatocellular carcinoma have a poor prognosis, and treatments with long-term benefits are needed. We report results from the preplanned interim analysis of the CheckMate 9DW trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line setting.
11. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Ashish Sarraju.;Danielle Brennan.;Kierstyn Hayden.;Amanda Stronczek.;Anne C Goldberg.;Erin D Michos.;Darren K McGuire.;Denise Mason.;Grace Tercek.;Stephen J Nicholls.;Douglas Kling.;Annie L Neild.;John Kastelein.;Michael Davidson.;Marc Ditmarsch.;Steven E Nissen.
来源: Lancet. 2025年405卷10491期1757-1768页
Reducing LDL cholesterol prevents atherosclerotic cardiovascular disease (ASCVD) events. The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose combination (FDC) of obicetrapib, a CETP inhibitor, and ezetimibe.
12. Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
作者: Graham S Cooke.;Le Manh Hung.;Barnaby Flower.;Leanne McCabe.;Vu Thi Kim Hang.;Vo Thi Thu.;Dang Trong Thuan.;Nguyen Thanh Dung.;Le Thanh Phuong.;Dao Bach Khoa.;Nguyen Thi Chau An.;Pham Ngoc Thach.;Vu Thi Thu Huong.;Dang Thi Bich.;Nguyen Kim Tuyen.;M Azim Ansari.;Chau Le Ngoc.;Vo Minh Quang.;Nguyen Thi Ngoc Phuong.;Le Thi Thao.;Nguyen Bao Tran.;Evelyne Kestelyn.;Cherry Kingsley.;Rogier Van Doorn.;Motiur Rahman.;Sarah L Pett.;Guy E Thwaites.;Eleanor Barnes.;Jeremy N Day.;Nguyen Van Vinh Chau.;A Sarah Walker.
来源: Lancet. 2025年405卷10491期1769-1780页
WHO recommends treating hepatitis C infection with one of three antiviral combinations for 8-12 weeks. No randomised trials have compared these regimens, and high cure rates might be achievable with shorter durations of therapy. We aimed to compare sofosbuvir-daclatasvir with sofosbuvir-velpatasvir, and to evaluate potential novel treatment strategies.
13. Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
作者: Jason Gardosi.;Lauren Jade Ewington.;Katie Booth.;Debra Bick.;George Bouliotis.;Emily Butler.;Sanjeev Deshpande.;Hanna Ellson.;Joanne Fisher.;Adam Gornall.;Ranjit Lall.;Hema Mistry.;Seyran Naghdi.;Stavros Petrou.;Anne-Marie Slowther.;Sara Wood.;Martin Underwood.;Siobhan Quenby.
来源: Lancet. 2025年405卷10491期1743-1756页
The benefits and harms of early induction of labour to reduce shoulder dystocia in fetuses suspected to be large for gestational age (LGA) are uncertain. We aimed to investigate whether early induction of labour is associated with a reduced risk of shoulder dystocia compared with standard care.
14. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
作者: Ana Maria Giménez-Arnau.;Andreas Pinter.;Wiebke Sondermann.;Ziad Reguiai.;Richard Woolf.;Charles Lynde.;Franz J Legat.;Antonio Costanzo.;Juan F Silvestre.;Natja Mellerup.;Marie Louise Østerdal.;Ursula Plohberger.;Lasse Ryttig.;Andrea Bauer.; .
来源: Lancet. 2025年405卷10490期1676-1688页
Chronic hand eczema is a heterogeneous, fluctuating, and long-lasting disease affecting the hands and wrists that substantially affects quality of life. For severe chronic hand eczema, topical corticosteroids are often unsatisfactory and systemic treatment can be required. The aim of the head-to-head, phase 3 DELTA FORCE trial was to evaluate the efficacy and safety of topical delgocitinib cream versus oral alitretinoin, the only currently approved systemic drug for severe chronic hand eczema.
15. Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial.
作者: Catherine Arundel.;Laura Mandefield.;Caroline Fairhurst.;Kalpita Baird.;Athanasios Gkekas.;Pedro Saramago.;Ian Chetter.; .
来源: Lancet. 2025年405卷10490期1689-1699页
Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy (NPWT) has increasingly been used as a treatment despite an absence of comparative evidence of effectiveness. We evaluated the effectiveness of NPWT compared with usual care for improving time to wound healing in patients with an SWHSI.
16. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
作者: Jonathan D C Ross.;Janet Wilson.;Kimberly A Workowski.;Stephanie N Taylor.;David A Lewis.;Sally Gatsi.;William Flight.;Nicole E Scangarella-Oman.;Charles Jakielaszek.;Dan Lythgoe.;Marcy Powell.;Salim Janmohamed.;Judith Absalon.;Caroline Perry.
来源: Lancet. 2025年405卷10489期1608-1620页
Gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antibacterial that inhibits bacterial DNA replication, was shown to be efficacious and well tolerated in the treatment of uncomplicated urinary tract infections. We evaluated the efficacy and safety of gepotidacin for the treatment of uncomplicated urogenital gonorrhoea.
17. SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.
作者: Christian Juhl Terkelsen.;Philip Freeman.;Jordi Sanchez Dahl.;Troels Thim.;Bjarne Linde Nørgaard.;Nils Sofus Borg Mogensen.;Mariann Tang.;Ashkan Eftekhari.;Jonas Agerlund Povlsen.;Steen Hvitfeldt Poulsen.;Lars Pedersen.;Jakob Hjort.;Julia Ellert.;Evald Høj Christiansen.;Henrik Toft Sørensen.;Henrik Nissen.
来源: Lancet. 2025年405卷10487期1362-1372页
Transcatheter aortic valve implantation (TAVI) is a guideline-directed treatment for severe aortic stenosis and degenerated aortic bioprostheses. When new transcatheter heart valve (THV) platforms for TAVI are launched, they should be compared with best-in-practice contemporary THVs for their short-term and long-term performance. The COMPARE-TAVI 1 trial was designed to provide a head-to-head comparison of the SAPIEN 3 or SAPIEN 3 Ultra THVs and the Myval or Myval Octacor THVs.
18. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.
作者: Kausik K Ray.;Ena Oru.;Robert S Rosenson.;Jeremiah Jones.;Xiaosu Ma.;Jennie Walgren.;Axel Haupt.;Subodh Verma.;Daniel Gaudet.;Stephen J Nicholls.;Giacomo Ruotolo.
来源: Lancet. 2025年405卷10489期1594-1607页
Mixed dyslipidaemia, characterised by elevated concentrations of circulating triglycerides and LDL cholesterol (LDL-C), is associated with an increased risk of atherosclerotic cardiovascular disease. Solbinsiran, a GalNAc-conjugated small interfering RNA targeting hepatic angiopoietin-like protein 3 (ANGPTL3), reduced triglycerides and LDL-C concentrations in a phase 1 study. This study aimed to assess the durability and efficacy of solbinsiran in reducing concentrations of atherogenic lipoproteins in adults with mixed dyslipidaemia.
19. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
作者: Ki Hong Choi.;Yong Hwan Park.;Jong-Young Lee.;Jin-Ok Jeong.;Chan Joon Kim.;Kyeong Ho Yun.;Han Cheol Lee.;Kiyuk Chang.;Mahn-Won Park.;Jang-Whan Bae.;Joon-Hyung Doh.;Byung Ryul Cho.;Hee-Yeol Kim.;Weon Kim.;Ung Kim.;Seung-Woon Rha.;Young Joon Hong.;Hyun-Jong Lee.;Sung Gyun Ahn.;Doo-Il Kim.;Jang Hyun Cho.;Sung Ho Her.;Doo Soo Jeon.;Seung Hwan Han.;Jin-Bae Lee.;Cheol Whan Lee.;Danbee Kang.;Joo Myung Lee.;Taek Kyu Park.;Jeong Hoon Yang.;Soo-Youn Lee.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.; .
来源: Lancet. 2025年405卷10486期1252-1263页
The optimal strategy for long-term antiplatelet maintenance for patients who underwent percutaneous coronary intervention (PCI) remains uncertain. This study aimed to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI with drug-eluting stents.
20. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
作者: William F Fearon.;Frederik M Zimmermann.;Victoria Y Ding.;Kuniaki Takahashi.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavičius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angerås.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.
来源: Lancet. 2025年405卷10488期1481-1490页
Long-term outcomes following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) might be changing because of improved techniques and better medical therapy. This final prespecified analysis of the Fractional Flow Reserve (FFR) versus Angiography for Multivessel Evaluation (FAME) 3 trial aimed to reassess their comparative effectiveness at 5 years.
|